Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study by Salyka Sengsayadeth, Katie.

Slides:

Advertisements

Similar presentations

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,

Advertisements

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia by Nathalie Dhédin, Anne Huynh, Sébastien.

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic.

Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)‏ by Peter Paschka,

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic.

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.

Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow.

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin.

Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia by Sebastian.

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

Prediction Of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Related Mortality in Acute Leukemia: Generation Of a Machine Learning-Based.

Allogeneic Hematopoietic Cell Transplantation in Patients Age Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous.

Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML – Results Of The Bridge.

Nonmyeloablative conditioning for relapsed follicular lymphoma

Biology of Blood and Marrow Transplantation

Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL by Eduardo.

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study.

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial by Peter Dreger,

Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide,

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

How I treat refractory CLL

Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity.

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic.

Activity of eltrombopag in severe aplastic anemia

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis Marie Robin, Raphaël Porcher, Annalisa Ruggeri, Didier Blaise,

by Alex Aleshin, and Peter L. Greenberg

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A.

Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases by John A. Snowden, Manuela Badoglio,

Cytotoxic T-Lymphocyte Antigen-4 Single Nucleotide Polymorphisms Are Not Associated with Outcomes after Unrelated Donor Transplantation: A Center for.

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity by Mary Eapen, Ruta Brazauskas, Michael.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation Aline Clavert, Zinaida Peric, Eolia.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide by Shannon R. McCurdy, Mei-Jie Zhang, Andrew.

Volume 2(Supplement 1):1-3

Predictive Limitations of Hematopoietic Stem Cell Transplantation Associated Mortality: A Machine Learning in-Silico Analysis of the EBMT - Acute Leukemia.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia by Saurabh Chhabra, Kwang Woo.

Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte.

Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? by Tara M. Robinson, Ephraim J. Fuchs,

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1 by Jurjen Versluis, Myriam Labopin, Annalisa Ruggeri,

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute.

Biology of Blood and Marrow Transplantation

Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion Laurent Garderet, Dimitris Ziagkos, Anja van Biezen, Simona.

Patrick J. Stiff, Manza-A. Agovi, Karen H

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL by Peter Dreger, Anna Sureda, Kwang.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

by Jan J. Cornelissen, and Didier Blaise

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation by Roni Shouval, Joshua A. Fein,

Volume 2(Supplement 1):4-7

Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation.

Presentation transcript:

Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study by Salyka Sengsayadeth, Katie S. Gatwood, Ariane Boumendil, Myriam Labopin, Jürgen Finke, Arnold Ganser, Matthias Stelljes, Gerhard Ehninger, Dietrich Beelen, Dietger Niederwieser, Didier Blaise, Peter Dreger, Ghulam Mufti, Patrice Chevallier, Audrey Mailhol, Maria H. Gilleece, Norbert Gorin, Jordi Esteve, Fabio Ciceri, Frederic Baron, Christoph Schmid, Sebastian Giebel, Mohamad Mohty, Bipin N. Savani, and Arnon Nagler BloodAdv Volume 2(16):2127-2135 August 28, 2018 © 2018 by The American Society of Hematology

Salyka Sengsayadeth et al. Blood Adv 2018;2:2127-2135 © 2018 by The American Society of Hematology

Cumulative incidence of relapse. Salyka Sengsayadeth et al. Blood Adv 2018;2:2127-2135 © 2018 by The American Society of Hematology

Probability of LFS. Probability of LFS. Salyka Sengsayadeth et al. Blood Adv 2018;2:2127-2135 © 2018 by The American Society of Hematology

Probability of OS. Probability of OS. Salyka Sengsayadeth et al. Blood Adv 2018;2:2127-2135 © 2018 by The American Society of Hematology

Cumulative incidence of nonrelapse mortality. Salyka Sengsayadeth et al. Blood Adv 2018;2:2127-2135 © 2018 by The American Society of Hematology